BofA analyst Michael Ryskin lowered the firm’s price target on 10x Genomics (TXG) to $12 from $16 and keeps a Neutral rating on the shares.

Genomics Market Liquid Biopsy Liquid biopsy is a non-invasive method for detecting cancer by analyzing blood samples for genetic mutations ...

Learn about metabolomics, biology's fourth language that has remained vastly untapped up until now and could accelerate ...

A new multicenter study by researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with the Clinical ...

BofA lowered the firm’s price target on NeoGenomics (NEO) to $12 from $16 and keeps a Neutral rating on the shares. Sentiment for Life Sciences ...

Developed by Weill Cornell Medicine and the New York Genome Center, the approach is not only more accurate than previous ...

A major new study has revealed that the genes we inherit at birth play a much larger role in cancer than previously ...

The much-publicized introduction of genetically modified cubs that share features of extinct dire wolves sparked claims ...

Under the collaboration, Biostate AI will sequence patient samples from the ACP Repository, one of the world's largest and most comprehensive MS-related collections of biospecimens and clinical data.

According to Weill Cornell, liquid biopsy technology, which is based on blood tests for early cancer detection, has faced ...

A study by scientists at the Herbert Irving Comprehensive Cancer Center (HICCC) introduces a more cost-effective, scalable ...

Novel tools that allow neuron-specific investigations of the structure controlling sleep regulation in fruit flies reveal the extent of neuronal heterogeneity.